Technology Infrastructure

Approximately 60% of the Institute’s campus comprises new construction or newly renovated space, providing the essential foundation for further progress. Furthermore, RPCI’s investment in research-related resources ensures the delivery of rapid, highly accurate, cost- effective support services in several areas:

  • The NMR Resource provides instrumentation and software for acquiring and processing nuclear magnetic resonance (NMR) spectra, molecular modeling and three-dimensional biomolecular analysis, and acquiring and processing NMR data of biofluids (metabonomics). Two high-resolution NMR spectrometers (Bruker-400 and AMX-600) are available. This resource is critical to such projects as the ongoing search for new agents to improve the effectiveness of biophysical therapies.
  • The Biopolymer Resource provides advice and technical services in DNA sequencing, synthesis, and characterization of oligonucleotides and peptides; the isolation, purification and characterization of proteins and peptides; mass spectrometry of synthetic organics, drug and drug metabolites (pharmacokinetic studies); and peptides and proteins (proteomics). An area that has been targeted for further development is that of proteomics, particularly as it relates to the use and applications of mass spectrometry.
  • The Gene Expression Resource provides bioinformatics and microarray technology to RPCI researchers at an affordable cost, enabling them to analyze large sets of data to produce meaningful results from experiments. This resource is important for identifying genetic markers that will respond favorably to therapy.
  • The Microarray and Genomics Resource supplies the technology researchers need to pinpoint the genetic mechanisms involved in the development and progression of cancer. This helps identify potential genetic targets for chemoprevention. Projects supported by this resource include the search for an effective treatment for multi-drug-resistant leukemia.
  • The Gene Targeting and Transgenics Resource produces genetically modified mice not available in most labs to provide the basis for new cancer models. Of special interest are two transgenic models that mimic chromosome rearrangements associated with specific human cancers.
  • The Laboratory Animal Resource maintains an inventory of 21,000 research animals, primarily highly specialized mouse colonies.
  • The Preclinical Imaging Facilty provides high-resolution, small-animal MR and fluorescent imaging relevant to improved methods of cancer detection and efficient delivery of chemotherapeutic agents.
  • The Pathology Resource Network maintains an extensive bank of human tissue specimens that enable scientists to better understand the cellular and molecular changes that lead to cancer. It is essential to such projects as the search for molecular markers to enhance the accuracy in diagnosis and prognosis, and the delivery of drugs and vaccines.
  • The Biostatistics Resource analyzes clinical and scientific data, providing biostatistical and biomathematical support necessary for genomic data mining. It supports such projects as the development of new photosensitizing agents for the treatment of solid-tumor malignancies.

Onsite availability of these resources ensures rapid delivery of service and stronger communication between scientists and those who provide research support.